You're describing a chemical compound with a very specific structure. It's not a commonly known compound with a simple, easily pronounceable name, so it's best to refer to it by its chemical structure.
**Let's break down the structure:**
* **1-[1-ethyl-4-[4-(4-methoxyphenyl)-1-piperazinyl]-6-methyl-2-sulfanylidene-5-pyrimidinyl]ethanone** is a complex molecule with a pyrimidine core, a piperazine ring, a phenyl group, and a carbonyl group (ketone).
* **Pyrimidine:** A heterocyclic ring system containing nitrogen atoms. This structure is important in various biological molecules like DNA and RNA.
* **Piperazine:** A six-membered ring containing two nitrogen atoms. It's often found in pharmaceutical compounds.
* **Phenyl group:** A six-membered aromatic ring.
* **Methoxyphenyl group:** A phenyl group with a methoxy (-OCH3) substituent.
* **Sulfanylidene:** This indicates a sulfur atom double-bonded to a carbon atom within the pyrimidine ring.
* **Ethanone:** This indicates the presence of a ketone group (C=O) attached to an ethyl group (-CH2CH3).
**Importance for research:**
Given the complexity of the compound's structure, it likely represents a **potential drug candidate** undergoing research.
Here's why this type of molecule is often investigated:
* **Biological activity:** The combination of various functional groups within the molecule could potentially interact with biological targets in the body.
* **Pharmacological properties:** The molecule might possess properties that make it a suitable drug, such as bioavailability, target specificity, and lack of adverse effects.
* **Therapeutic potential:** Researchers might be investigating this compound for its potential in treating various conditions.
**To find out more, you would need to:**
1. **Search for the compound using its chemical structure.** This can be done through databases like PubChem or SciFinder.
2. **Check scientific publications.** Searching for the structure or related keywords might reveal research papers discussing this specific compound or similar molecules.
**Remember:** This compound is likely not a known drug, but rather a molecule under investigation. More information is required to understand its specific role in research and potential therapeutic applications.
ID Source | ID |
---|---|
PubMed CID | 1213862 |
CHEMBL ID | 1506624 |
CHEBI ID | 114331 |
Synonym |
---|
HMS2608A10 |
smr000292661 |
MLS000663519 |
AJ-292/41812123 |
1-{1-ethyl-4-[4-(4-methoxyphenyl)-1-piperazinyl]-6-methyl-2-thioxo-1,2-dihydro-5-pyrimidinyl}ethanone |
CHEBI:114331 |
AKOS001689704 |
1-[1-ethyl-4-[4-(4-methoxyphenyl)piperazin-1-yl]-6-methyl-2-sulfanylidenepyrimidin-5-yl]ethanone |
CCG-23675 |
CHEMBL1506624 |
1-{1-ethyl-4-[4-(4-methoxyphenyl)piperazin-1-yl]-6-methyl-2-sulfanylidene-1,2-dihydropyrimidin-5-yl}ethan-1-one |
Q27195730 |
1-[1-ethyl-4-[4-(4-methoxyphenyl)-1-piperazinyl]-6-methyl-2-sulfanylidene-5-pyrimidinyl]ethanone |
1-{1-ethyl-4-[4-(4-methoxyphenyl)piperazin-1-yl]-6-methyl-2-thioxo-1,2-dihydropyrimidin-5-yl}ethanone |
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.0919 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 22.3872 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
TDP1 protein | Homo sapiens (human) | Potency | 8.1995 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 28.1838 | 0.1800 | 13.5574 | 39.8107 | AID1460; AID1468 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 12.5893 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 25.1189 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 50.1187 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 35.4813 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 8.4368 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 11.2202 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.0259 | 11.2398 | 31.6228 | AID602313 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 4.4668 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
negative regulation of inflammatory response to antigenic stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
renal water homeostasis | Guanine nucleotide-binding protein G | Homo sapiens (human) |
G protein-coupled receptor signaling pathway | Guanine nucleotide-binding protein G | Homo sapiens (human) |
regulation of insulin secretion | Guanine nucleotide-binding protein G | Homo sapiens (human) |
cellular response to glucagon stimulus | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
G protein activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
adenylate cyclase activator activity | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Guanine nucleotide-binding protein G | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |